Drugs News and Research

RSS

MSU launches research and training program to address product counterfeiting

Michigan State University has launched the nation's first comprehensive research and training program designed to address product counterfeiting-- which the FBI has called "the crime of the 21st century."

10 Feb 2010

Research opens door for advancement of new category of painkillers

Research led by a scientist at Barrow Neurological Institute at St. Joseph's Hospital and Medical Center has opened the door for the advancement of a new category of painkillers, called TRPV1 antagonists.

10 Feb 2010

G7 forgives Haiti's bilateral loans to support aid effort

At a press conference on Saturday, "Canadian Finance Minister Jim Flaherty said he and his G-7 colleagues would forgive bilateral loans extended to poverty-stricken Haiti, which estimates it could have lost 200,000 residents in the major earthquake that hit last month," Dow Jones Newswires reports.

10 Feb 2010

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

A joint GA²LEN /EAACI report to be published in "Allergy" and available online on 8 February reviews new data on the treatment of allergies with older antihistamines compared with newer, second-generation H1-antihistamines. The research was funded by GA²LEN, an EU-funded Network of Excellence.

10 Feb 2010

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Excelsior Medical Corporation, one of the leading manufacturers of pre-filled catheter flush syringes, today announced that it has received a Medical Device License from Health Canada for its new, pre-filled catheter lock syringe to be sold in the Canadian marketplace.

10 Feb 2010

Study could lead to new therapeutic strategies for Parkinson's disease

A new study from The Montreal Neurological Institute and Hospital - The Neuro - at McGill University is the first to discover a molecular link between Parkinson's disease and defects in the ability of nerve cells to communicate.

10 Feb 2010

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

Palatin Technologies, Inc. today announced the completion of first cohort dosing in a placebo-controlled, multiple dose study of bremelanotide, its experimental treatment for sexual dysfunction. The primary endpoint in this double-blind safety study is evaluation of blood pressure effects of subcutaneous bremelanotide in men between 45 and 65 years old. The study will also evaluate consistency of plasma exposure of bremelanotide given as repeated subcutaneous injections.

10 Feb 2010

FDA expands indication for Crestor

On Feb. 8 the U.S. Food and Drug Administration approved the cholesterol-lowering medication Crestor (rosuvastatin) for some patients who are at increased risk of heart disease but have not been diagnosed with it.

10 Feb 2010

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Delcath Systems, Inc. (DCTH), a medical technology company testing its proprietary treatment system for primary and metastatic cancers to the liver, announced today the signing of its first research, distribution, sales and marketing agreement for its Percutaneous Hepatic Perfusion (PHP) System (the Delcath PHP System™). The agreement grants Chi-Fu Trading Co., Ltd. the exclusive right to market and sell the Delcath PHP System in Taiwan for hepatic malignancies and infectious disease upon Taiwan Food and Drug Administration (TFDA) approval, and any other approved use, with a conditional option for Singapore.

9 Feb 2010

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

ExThera Medical announced today that the results of a preliminary study (“Cytokines in blood from septic patients interact with surface immobilized heparin”) of its proprietary medical device, Seraph™ extracorporeal affinity therapy, have been published in the current issue of the Journal of the American Society for Artificial Organs (Jan.-Feb. 2010).

9 Feb 2010

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

In the history of humans fighting against cancer, the relationship between tobaccos and cancer has been an important subject for the academic and clinical research. By understanding the mechanism of why cancer is caused by tobaccos, scientists around the world all anticipate to solve the mystery of cancer and find the way of prevention and cure.

9 Feb 2010

Racial disparities continue in U.S. cancer screening practices

The incidence of advanced breast cancer diagnosis among black women remained 30 percent to 90 percent higher compared to white women between 1992 and 2004, according to new findings by researchers at Fred Hutchinson Cancer Research Center. In addition, the disparity in the incidence of advance colorectal cancer actually widened over this time period as rates fell among whites but increased slightly among blacks.

9 Feb 2010

Findings point towards new therapeutic approach for breast and prostate cancer

In a new approach to developing treatments for breast cancer, prostate cancer and enlarged hearts, Loyola University Stritch School of Medicine researchers are zeroing in on a workhorse protein called RSK.

9 Feb 2010

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that the United States Food and Drug Administration informed CTI that due to severe weather conditions in the Washington, D.C. area, the FDA is postponing the Oncologic Drugs Advisory Committee ("ODAC") meeting that was to be held on Wednesday, February 10, 2010 to discuss the pixantrone New Drug Application ("NDA"). The FDA indicated that it intends to reschedule the meeting as soon as the FDA can determine a schedule that will allow them to reconvene the advisory panel.

9 Feb 2010

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

NexBio, Inc. today announced the issuance by the United States Patent and Trademark Office of United States Patent No. 7,645,448 entitled "Class of Therapeutic Protein Based Molecules". This patent covers NexBio's sialidase pharmaceutical compositions, including its lead compound DAS181 (Fludase®), and methods of treating or preventing viral infection by influenza and parainfluenza with such compositions.

9 Feb 2010

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

KineMed, Inc. a translational and personalized medicine development company, today announced a broadening of its collaboration with Bristol-Myers Squibb Company (NYSE: BMY) in the area of Alzheimer’s disease and other neurodegenerative conditions.

9 Feb 2010

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Debiopharm Group, a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, today announced the signature of an exclusive licence agreement with Novartis for the development, manufacture and commercialisation of Debio 025 (alisporivir), a selective, first-in-class cyclophilin (Cyp) inhibitor with a potent anti-hepatitis C virus (HCV) effect. The product is currently in phase 2b clinical development for the treatment of hepatitis C. Debiopharm granted Novartis worldwide commercialisation rights to Debio 025 except for Japan.

9 Feb 2010

Doctors do not follow evidence-based guidelines for treating low back pain, says report

Australian general practitioners often treat patients with low back pain in a manner that does not appear to match the care endorsed by international clinical guidelines, according to a report in the February 8 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

9 Feb 2010

60% of pregnant women never tested for CHD

Three out of five women who have given birth to a child with a congenital heart defect (CHD) -- the number-one birth defect and leading killer of infants and newborns -- were never tested for the defect during pregnancy. This is according to a survey just released by Little Hearts, Inc., a national organization that provides support, education, resources, networking and hope to families affected by congenital heart defects.

9 Feb 2010

Study indicates pain treatment may vary in Latino and white children post surgery

Differences might exist in the amount of pain medicine given to Latino and white children after surgery, found a new, small study in which Latino children received 30 percent less opioid analgesics (morphine or morphine-like drugs) than white children did.

9 Feb 2010

Drugs News and Research

MSU launches research and training program to address product counterfeiting

Research opens door for advancement of new category of painkillers

G7 forgives Haiti's bilateral loans to support aid effort

GA²LEN and EAACI warn: Older antihistamines in OTC allergy medications may be hazardous

Excelsior Medical receives Canadian marketing license for new, pre-filled catheter lock syringe

Study could lead to new therapeutic strategies for Parkinson's disease

Palatin Technologies completes first cohort dosing in bremelanotide trial for sexual dysfunction

FDA expands indication for Crestor

Chi-Fu Trading to market and sell Delcath PHP Systems in Taiwan

Preliminary study results of ExThera Medical's Seraph extracorporeal affinity therapy published

NNK induces epigenetic alteration during cancer formation and inhibits tumor suppressor genes

Racial disparities continue in U.S. cancer screening practices

Findings point towards new therapeutic approach for breast and prostate cancer

Cell Therapeutics' pixantrone NDA: FDA postpones ODAC meeting due to severe weather conditions

USPTO awards NexBio patent covering sialidase pharmaceutical compositions and methods of treating influenza

KineMed, Bristol-Myers Squibb broaden collaboration to develop novel mechanisms for Alzheimer’s disease

Debiopharm Group signs exclusive licence agreement with Novartis for alisporivir

Doctors do not follow evidence-based guidelines for treating low back pain, says report

60% of pregnant women never tested for CHD

Study indicates pain treatment may vary in Latino and white children post surgery

Drug Discovery - Second Edition eBook

Leveraging the power of automation to boost research

Automating research - solutions and best practices

How can microdialysis benefit drug development

Latest News